Literature DB >> 6966615

Depressed immunological defence mechanisms in mice with experimentally induced diabetes.

O Saiki, S Negoro, I Tsuyuguchi, Y Yamamura.   

Abstract

Persistent diabetes mellitus with marked hyperglycemia was induced in mice by the administration of streptozotocin. In these streptozotocin-induced diabetic mice, resistance to tubercle bacillus challenge and primary as well as secondardy humoral immune responses against foreign erythrocytes were markedly depressed. The T-cell function in delayed hypersensitivity to 2,4-dinitro-1-fluorobenzene and bacterial phagocytic activity or peritoneal macrophages were markedly depressed. In contrast, the B-cell function in antibody production against T-independent antigen and the intracellular killing of bacteria in peritoneal macrophages were intact. We concluded that depression of the T-cell function or the phagocytic activity of macrophages or both may be the main immunological defect in these mice.

Entities:  

Mesh:

Year:  1980        PMID: 6966615      PMCID: PMC550901          DOI: 10.1128/iai.28.1.127-131.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  THE PHAGOCYTIC ACTIVITY OF POLYMORPHONUCLEAR LEUKOCYTES OBTAINED FROM PATIENTS WITH DIABETES MELLITUS.

Authors:  J D BYBEE; D E ROGERS
Journal:  J Lab Clin Med       Date:  1964-07

2.  Studies of the resistance to infection in diabetes mellitus: local exudative cellular response.

Authors:  P E PERILLIE; J P NOLAN; S C FINCH
Journal:  J Lab Clin Med       Date:  1962-06

3.  Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients.

Authors:  A C MacCuish; S J Urbaniak; C J Campbell; L J Duncan; W J Irvine
Journal:  Diabetes       Date:  1974-08       Impact factor: 9.461

4.  Glucose metabolism in leucocytes from patients with diabetes mellitus, with and without hypercholesteremia.

Authors:  J F Munroe; J C Shipp
Journal:  Diabetes       Date:  1965-09       Impact factor: 9.461

5.  IMMUNITY IN DIABETES: INFLUENCE OF DIABETES ON THE DEVELOPMENT OF ANTIBACTERIAL PROPERTIES IN THE BLOOD.

Authors:  R Richardson
Journal:  J Clin Invest       Date:  1933-11       Impact factor: 14.808

6.  Streptozotocin-induced diabetes mellitus and the host-parasite relation in murine schistosomiasis mansoni.

Authors:  A A Mahmoud; A W Cheever; K S Warren
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

7.  Streptozotocin diabetes. Correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide.

Authors:  T Anderson; P S Schein; M G McMenamin; D A Cooney
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

8.  Induced and spontaneous diabetes mellitus and suppression of cell-mediated immunologic responses. Granuloma formation, delayed dermal reactivity and allograft rejection.

Authors:  A A Mahmoud; H M Rodman; M A Mandel; K S Warren
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

9.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

10.  Studies on the effect of experimental nonketotic diabetes mellitus on antibacterial defense. I. Demonstration of a defect in phagocytosis.

Authors:  R H Drachman; R K Root; W B Wood
Journal:  J Exp Med       Date:  1966-08-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

2.  Insulin treatment modulates the host immune system to enhance Pseudomonas aeruginosa wound biofilms.

Authors:  Chase Watters; Jake A Everett; Cecily Haley; Allie Clinton; Kendra P Rumbaugh
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

3.  Differential Impact of Chronic Hyperglycemia on Humoral Versus Cellular Primary Alloimmunity.

Authors:  Nicholas H Bishop; Michelle K Nelsen; K Scott Beard; Marilyne Coulombe; Ronald G Gill
Journal:  Diabetes       Date:  2017-01-09       Impact factor: 9.461

Review 4.  Diabetes and immunity to tuberculosis.

Authors:  Nuria Martinez; Hardy Kornfeld
Journal:  Eur J Immunol       Date:  2014-02-16       Impact factor: 5.532

Review 5.  Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus.

Authors:  D W Drell; A L Notkins
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

6.  Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis.

Authors:  Therese Vallerskog; Gregory W Martens; Hardy Kornfeld
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

7.  Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis.

Authors:  S Yamashiro; K Kawakami; K Uezu; T Kinjo; K Miyagi; K Nakamura; A Saito
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

8.  Differential effect of hyperglycaemia on the immune response in an experimental model of diabetes in BALB/cByJ and C57Bl/6J mice: participation of oxidative stress.

Authors:  M R Rubinstein; A M Genaro; M R Wald
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

9.  Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects.

Authors:  R J Al-Attiyah; A S Mustafa
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

10.  Tuberculosis susceptibility of diabetic mice.

Authors:  Gregory W Martens; Meltem Cevik Arikan; Jinhee Lee; Fucheng Ren; Dale Greiner; Hardy Kornfeld
Journal:  Am J Respir Cell Mol Biol       Date:  2007-06-21       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.